Semler Scientific Inc (SMLR) is Resumed by Rodman & Renshaw to Buy, Price Target at $8

Semler Scientific Inc (SMLR) was Resumed by Rodman & Renshaw to “Buy” and the brokerage firm has set the Price Target at $8. Rodman & Renshaw advised their investors in a research report released on Apr 15, 2016.

In a different news, on Nov 4, 2015, Aidan Matthew Collins (director) purchased 1,000 shares at $3.38 per share price.

Semler Scientific Inc. is a medical risk assessment company. The Company develops manufactures and markets products that assist healthcare providers in monitoring patients and evaluating chronic diseases. The Company markets and licenses FloChec which is a United States Food and Drug Administration (FDA) cleared product. FloChec is a four-minute in-office blood flow test. FloChec is used in the office setting to allow providers to measure arterial blood flow in the extremities and is a tool for internists and primary care physicians to conduct blood flow measurements. It offers FloChec product to cardiologists internists nephrologists endocrinologists podiatrists and family practitioners. The Company’s FloChec features a sensor clamp that is placed on the toe or finger much like pulse oximetry devices. The Company provides FloChec product and services through salespersons and through its distributor.

Semler Scientific Inc

Leave a Reply

Semler Scientific Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Semler Scientific Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.